BofA Securities analyst Jason Gerberry raised the price target on Vaxcyte (NASDAQ: PCVX) to $140.00 (from $101.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE